Answers are grounded in this paper and cite their sources.
Osteosarcoma exhibits substantial metabolic heterogeneity, yet existing classification schemes typically rely on narrow pathway windows and lack cellular-source attribution. Here, we integrated bulk transcriptomes from 157 osteosarcoma tumors (PKUPH-OS, n = 70; TARGET-OS, n = 87), quantified pathway-level activity via single-sample gene set enrichment analysis (ssGSEA) across curated metabolic gene sets, and performed consensus clustering to identify three stable metabolic subtypes: Cholesterogenic (C1), characterized by mTORC1-associated lipid biosynthesis and invasion-related signaling; Redox-Catabolic (C2), dominated by detoxification, glutathione/ROS buffering, and enhanced catabolic programs alongside immune engagement; and OXPHOS-Active (C3), featuring coupled mitochondrial oxidative phosphorylation and proliferative programs. Clinically, C2 displayed favorable survival (3-year overall survival: 90.8%), whereas C1 (60.0%) and C3 (61.9%) followed adverse trajectories (overall survival, P = 0.0037; progression-free survival, P = 0.011). Single-cell RNA sequencing of 16,276 cells with inferCNV-supported malignant-cell anchoring revealed distinct cellular origins: C1 signatures mapped predominantly to stromal/mesenchymal populations, C2 signatures to immune cells, and C3 signatures to malignant tumor cells. These observations apply within osteosarcoma the well-recognized principle that bulk transcriptomic signatures reflect cellular composition, providing an explicit cell-of-origin map of metabolic subtypes that supports niche-resolved risk stratification and cell-aware therapeutic hypothesis generation.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: